Default company panoramic image
Ff2c4056 0e70 46ef 880e 6325c74ea64f

Innovimmune Biotherapeutics Holding, LLC

IND-enabling development of proprietary best-in-class oral INV-17 ROR gamma modulators & oral INV-88 MIF inhibitors for high-growth Autoimmune Diseases.

  • Stage Product In Development
  • Industry Biotechnology
  • Location NYC, NY, US
  • Currency USD
  • Founded 2010
  • Employees 8
  • Website

Company Summary

Innovimmune is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune and ImmunoInflammatory Diseases.


  • Default avatar
    Anderson Gaweco, M.D., Ph.D.
    Founder, President & CEO

  • Default avatar
    Jefferson Tilley, Ph.D.
    VP, Discovery Chemistry

  • 0401df19 14fa 42ff 9854 7030a6125186
    VP, Discovery Biology